APA
Díaz-Redondo T., Lavado-Valenzuela R., Jimenez B., Pascual T., Gálvez F., Falcón A., Alamo M. D. C., Morales C., Amerigo M., Pascual J., Sanchez-Muñoz A., González-Guerrero M., Vicioso L., Laborda A., Ortega M. V., Perez L., Fernandez-Martinez A., Chic N., Jerez J. M., Alvarez M., Prat A., Ribelles N. & Alba E. (2019). Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. : Frontiers in oncology.
Chicago
Díaz-Redondo Tamara, Lavado-Valenzuela Rocio, Jimenez Begoña, Pascual Tomas, Gálvez Fernando, Falcón Alejandro, Alamo Maria Del Carmen, Morales Cristina, Amerigo Marta, Pascual Javier, Sanchez-Muñoz Alfonso, González-Guerrero Macarena, Vicioso Luis, Laborda Aurora, Ortega Maria Victoria, Perez Lidia, Fernandez-Martinez Aranzazu, Chic Nuria, Jerez Jose Manuel, Alvarez Martina, Prat Aleix, Ribelles Nuria and Alba Emilio. 2019. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. : Frontiers in oncology.
Harvard
Díaz-Redondo T., Lavado-Valenzuela R., Jimenez B., Pascual T., Gálvez F., Falcón A., Alamo M. D. C., Morales C., Amerigo M., Pascual J., Sanchez-Muñoz A., González-Guerrero M., Vicioso L., Laborda A., Ortega M. V., Perez L., Fernandez-Martinez A., Chic N., Jerez J. M., Alvarez M., Prat A., Ribelles N. and Alba E. (2019). Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. : Frontiers in oncology.
MLA
Díaz-Redondo Tamara, Lavado-Valenzuela Rocio, Jimenez Begoña, Pascual Tomas, Gálvez Fernando, Falcón Alejandro, Alamo Maria Del Carmen, Morales Cristina, Amerigo Marta, Pascual Javier, Sanchez-Muñoz Alfonso, González-Guerrero Macarena, Vicioso Luis, Laborda Aurora, Ortega Maria Victoria, Perez Lidia, Fernandez-Martinez Aranzazu, Chic Nuria, Jerez Jose Manuel, Alvarez Martina, Prat Aleix, Ribelles Nuria and Alba Emilio. Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data. : Frontiers in oncology. 2019.